Search Results for "drug"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for drug. Results 2261 to 2270 of 2594 total matches.

In Brief: Propofol Revisited

   
The Medical Letter on Drugs and Therapeutics • Oct 17, 2011  (Issue 1375)
The Medical Letter® On Drugs and Therapeutics Volume 53 (Issue 1375) October 17, 2011 ...
A reader has asked us to review the use of propofol (Diprivan, and others) as a sedative agent for brief procedures, such as colonoscopy.First marketed more than 20 years ago,1 propofol has a rapid onset of action (patients usually lose consciousness in less then one minute) and a short duration of action with a rapid recovery (3-5 minutes) that makes it highly suitable for brief ambulatory procedures. Propofol is now the most commonly used parenteral anesthetic in the US.2 The main problems with its use have been pain on injection and bacterial contamination, both related to its lipid...
Med Lett Drugs Ther. 2011 Oct 17;53(1375):84 |  Show IntroductionHide Introduction

In Brief: Calcium and Vitamin D to Prevent Osteoporotic Fractures

   
The Medical Letter on Drugs and Therapeutics • Jun 25, 2012  (Issue 1393)
The Medical Letter® On Drugs and Therapeutics Volume 54 (Issue 1393) June 25, 2012 ...
The US Preventive Services Task Force (USPSTF) has issued a Draft Recommendation Statement saying, in effect, that community-dwelling women and men should not take calcium and vitamin D supplements for primary prevention of osteoporotic fractures because the evidence that they are helpful is insufficient and they increase the risk of kidney stones. The Medical Letter has said previously that there is no evidence that patients with an adequate intake of calcium (1000-1200 mg/day) and vitamin D (600-800 IU/day) will benefit from taking supplements.11. Drugs for postmenopausal osteoporosis. Treat...
Med Lett Drugs Ther. 2012 Jun 25;54(1393):52 |  Show IntroductionHide Introduction

In Brief: Two New Seasonal Influenza Vaccines

   
The Medical Letter on Drugs and Therapeutics • Feb 04, 2013  (Issue 1409)
The Medical Letter® On Drugs and Therapeutics Volume 55 (Issue 1409) February 4, 2013 ...
Two new trivalent influenza vaccines, Flucelvax (Novartis) and Flublok (Protein Sciences), will soon be available for prevention of seasonal influenza in adults ≥18 years old (Flucelvax) and 18-49 years old (Flublok). Unlike other available influenza vaccines, neither vaccine is produced in eggs, removing any concern regarding use in egg-allergic patients. Avoiding the use of eggs should allow for faster production of these 2 new vaccines, which could be especially beneficial during a pandemic.Flucelvax is prepared in a similar manner to other influenza vaccines, but the influenza virus is...
Med Lett Drugs Ther. 2013 Feb 4;55(1409):12 |  Show IntroductionHide Introduction

Treatment of COVID-19 in High-Risk Outpatients (online only)

   
The Medical Letter on Drugs and Therapeutics • Jan 28, 2022  (Issue 1643)
-Pugh C), patients taking strong CYP3A inducers4 or high-risk, highly CYP3A-dependent drugs (e.g ...
View the Treatment of COVID-19 in High-Risk Outpatients Chart
Med Lett Drugs Ther. 2022 Jan 28;64(1643):e1 |  Show IntroductionHide Introduction

In Brief: Oral Minoxidil for Hair Loss

   
The Medical Letter on Drugs and Therapeutics • Dec 26, 2022  (Issue 1666)
with an oral antiandrogenic drug such as spironolactone.1 Oral minoxidil, which is available by prescription ...
Topical minoxidil (Rogaine, and others), which is available over the counter, has been used for treatment of hair loss in men and women for more than 30 years. Recently published trials suggest that off-label use of a low dose of oral minoxidil may also be effective.
Med Lett Drugs Ther. 2022 Dec 26;64(1666):208 |  Show IntroductionHide Introduction

Comparison Chart: Interleukin (IL) Receptor Antagonists for Atopic Dermatitis (online only)

   
The Medical Letter on Drugs and Therapeutics • Feb 17, 2025  (Issue 1722)
Drug/Formulations Class Approved Age Efficacy at 16 Weeks1 Usual Adult Dosage Cost2 Dupilumab ...
View the Comparison Chart: Interleukin (IL) Receptor Antagonists for Atopic Dermatitis
Med Lett Drugs Ther. 2025 Feb 17;67(1722):e1   doi:10.58347/tml.2025.1722f |  Show IntroductionHide Introduction

High Altitude Sickness

   
The Medical Letter on Drugs and Therapeutics • Sep 04, 1992  (Issue 878)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Rapid exposure to altitudes more than 8,000 feet above sea level can cause serious medical problems. Since the last Medical Letter article on this subject (Vol. 30, page 89, 1988), some new information on prevention and treatment of these disorders has been reported.
Med Lett Drugs Ther. 1992 Sep 4;34(878):84-6 |  Show IntroductionHide Introduction

Radiofrequency Catheter Ablation for Treatment of Cardiac Arrhythmias

   
The Medical Letter on Drugs and Therapeutics • Apr 26, 1996  (Issue 973)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
In recent years, selective destruction of cardiac tissue by radiofrequency energy has become a routine procedure for treatment of some types of cardiac arrhythmias, particularly supraventricular tachycardias (MM Scheinman, Pacing Clin Electrophysiol, 18:1474, 1995).
Med Lett Drugs Ther. 1996 Apr 26;38(973):40-2 |  Show IntroductionHide Introduction

Insulin Glargine (Lantus), A New Long-acting Insulin

   
The Medical Letter on Drugs and Therapeutics • Aug 06, 2001  (Issue 1110)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Insulin Glargine (Lantus) is a new long-acting human insulin analog approved by the FDA for treatment of both type 1 and type 2 diabetes. Synthesized by recombinant DNA technology, it differs from human insulin at position 21 in the A-chain where asparagine is replaced by glycine and at the C-terminus of the B-chain where two arginines are added.
Med Lett Drugs Ther. 2001 Aug 6;43(1110):65-6 |  Show IntroductionHide Introduction

Twinrix: A Combination Hepatitis A and B Vaccine

   
The Medical Letter on Drugs and Therapeutics • Aug 06, 2001  (Issue 1110)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
A vaccine to prevent both Hepatitis A and Hepatitis B (Twinrix), previously licensed in Canada and Europe, is now available in the US for adults.
Med Lett Drugs Ther. 2001 Aug 6;43(1110):67-8 |  Show IntroductionHide Introduction